Heterocyclic compounds represented by the general formula (I)
wherein R stands for an optionally substituted aromatic heterocyclic group;
X stands for oxygen atom, an optionally oxidated sulfur atom, —C(═O)— or —CH(OH)—;
Y stands for CH or N;
m denotes an integer of 0 to 10:
n denotes an integer of 1 to 5:
cyclic group
stands for an optionally substituted aromatic azole group; and
ring A is optionally further substituted,
or salts thereof. The compound (I) possesses action of inhibiting tyrosine kinase and useful as antitumor agents.
Indole Sulfonamide Modulators of Progesterone Receptors
申请人:Bleisch Thomas John
公开号:US20090069400A1
公开(公告)日:2009-03-12
Compounds of Formula (I), wherein n is 1 or 2, and R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein, their preparation, pharmaceutical compositions, and methods of use are disclosed.
Indole sulfonamide modulators of progesterone receptors
申请人:Eli Lilly and Company
公开号:US07932284B2
公开(公告)日:2011-04-26
Compounds of Formula (I), wherein n is 1 or 2, and R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein, their preparation, pharmaceutical compositions, and methods of use are disclosed.
[EN] (HETERO)ARYLAMINO-CYCLOHEXYL-SULFONYL DERIVATIVES AS CCR6 INHIBITORS<br/>[FR] DÉRIVÉS D'(HÉTÉRO)ARYLAMINO-CYCLOHEXYL-SULFONYLE UTILES EN TANT QU'INHIBITEURS DE CCR6
申请人:QILU REGOR THERAPEUTICS INC
公开号:WO2022173849A1
公开(公告)日:2022-08-18
The present disclosure provides a compound of Formula (I) a pharmaceutically acceptable salt, or a stereoisomer and their use in, e.g. treating a condition, disease or disorder modulated at least in part by CCR6. This disclosure also features compositions containing the same as well as methods of using and making the same.